Autolus Therapeutics plc ADR (AUTL) saw an uptrend of 2.62% in the recent trading with $2350000.0 being its most recent. The current price level -53.00% lower than the highest price of $5.00 marked by the stock while trading over the past 52-weeks, whereas it is 112.67% higher than the lowest price of $1.11 the company dropped to over past 52-weeks. The latest news story on AUTL appeared in (Insider Monkey) under the title “Needham Reiterates a Buy Rating on Autolus Therapeutics (AUTL), Keeps the PT at $10” on Jun-24-25.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Strong Buy by 3 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.00 for the stock.
Autolus Therapeutics plc ADR Earnings – What Happened With AUTL
Coming around sales and income figures on AUTL Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor.
Autolus Therapeutics plc ADR – Insider Activity and Holdings
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 266.14 million. AUTL does have institutional investors; and they hold 60.22% of the stock.
As on 2024-06-30, SYNCONA PORTFOLIO LTD was the top most holder in Autolus Therapeutics plc ADR (NASDAQ:AUTL) with an ownership of 21.35 million shares of the company or 8.0243 of the stake worth $74.29 million. The filing also reveals BLACKSTONE INC. as the second largest holder in the company with a control over 7.7006 of the outstanding shares. Its stake is worth $71.29 million for having 20.49 million shares in hand.
WELLINGTON MANAGEMENT GROUP LLP also came holding a key position in the company during the recent quarter and it now holds 6.7248 of the outstanding shares. With this there are now 124.0 institutions which have possession in AUTL’s shares.
Key Metrics forAUTL
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, Autolus Therapeutics plc ADR has a debt to equity ratio of 0.84.
Technical Analysis of Autolus Therapeutics plc ADR (NASDAQ:AUTL) stock
To comprehend better with the trade moves and investors’ behavior, exploring the short, medium and long term technical indicators along with average volume of a stock is an effective way to make use of. When looking into those indicators for Autolus Therapeutics plc ADR (AUTL), we notice that the stock’s 20-day average volume is at 2,252,090 shares and 50% of short term indicators are suggesting the stock as Buy. And to end with, AUTL’s 100-day average volume are 1,962,863 shares.
